A fourth Covid-19 vaccine, NVX-CoV237, is to be assessed by the UK medicines regulator for distribution after late-stage trials showed an 89.3% efficacy rate in preventing coronavirus.

The jab from US firm Novavax is now going to be evaluated by the Medicines and Healthcare products Regulatory Agency (MHRA), the government said on 29 January.